



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Poloxamer 407

Cat. No.:	HY-D1005		
CAS No.:	9003-11-6		
Target:	LPL Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 110 mg/mL (Need ultrasonic)
In Vivo	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

Description	Poloxamer 407 is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8™ AM and Quest Rhod-4™ AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor <sup>[1][2]</sup> .
In Vitro	<p>Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).</p> <ol style="list-style-type: none"> <li>Dissolve 1 g of Poloxamer 407 in 10 mL distilled water to make a 10% (w/v) stock solution, or 2 g of Poloxamer 407 in 10 mL DMSO to make a 20% (w/v) stock solution. These may require heating from 40 to 50°C for about 30 minutes. Store solution at room temperature. Do not refrigerate or freeze the Poloxamer 407 solution since it may precipitate. If precipitation is observed, the precipitates can be dissolved by heating to 37°C and vortexing before use.</li> <li>Dilute the 10% or 20% Poloxamer 407 stock solution into the cell-loading buffer such as Hanks and 20 mM Hepes buffer (HHBS) at 1:1000 to 1:500 dilution to achieve a 0.02 to 0.04% working solution.</li> <li>The DMSO stock solution of AM ester is then diluted into the 0.02 to 0.04% working solution to achieve a final AM ester concentration between 1 μM and 10 μM. The final concentration of Poloxamer 407 is normally kept at or below 0.08%.</li> <li>The cells are incubated at a desired temperature for between 10 minutes and 1 hour. In general it is desirable to use the minimum amount of AM ester needed to achieve adequate fluorescence signal to noise levels.</li> <li>After labeling, the cells are washed with HHBS or fresh medium before starting the experiment.</li> </ol> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Poloxamer 407 (0.25 g/kg; i.p.; every other day for 7 weeks) induces hypertriglyceridemia but decreases atherosclerosis in Ldlr<sup>-/-</sup> mice<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

Animal Model:	Ldlr <sup>-/-</sup> mice <sup>[2]</sup>
Dosage:	0.25 g/kg
Administration:	Intraperitoneal injection, every other day for 7 weeks
Result:	Mice tended to have a lower body weight and had smaller epididymal fat pads compared to the saline controls, and had reduced atherosclerosis.

## CUSTOMER VALIDATION

- Dig Dis Sci. 2022 Jul 4.
- Research Square Preprint. 2023 Jul 5.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Peng X, et al. Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr<sup>-/-</sup> Mice. *Cells*. 2022 May 30;11(11):1795.

[2]. Antunes FE, et al. Gels of Pluronic F127 and nonionic surfactants from rheological characterization to controlled drug permeation. *Colloids Surf B Biointerfaces*. 2011 Oct 1;87(1):42-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA